Abiomed
Clinical trials sponsored by Abiomed, explained in plain language.
A medical device company specializing in heart pumps, now part of Johnson & Johnson.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Heart pump may boost survival in complex stenting Results expected Oct 2026 (estimated)
- New heart pump aims to make risky artery procedures safer Results expected Oct 2026 (estimated)
- New heart pump aims to make risky artery procedures safer Results expected Dec 2026 (estimated)
- Heart pump data study aims to sharpen shock monitoring Results expected Jun 2027 (estimated)
-
New heart pump aims to make risky artery procedures safer
Disease control OngoingThis study tests a temporary heart pump called Impella ECP in 100 adults undergoing high-risk angioplasty. The pump helps maintain blood flow during the procedure. Researchers are checking if the device is safe and works as intended, with follow-up for 30 days after the procedure…
Sponsor: Abiomed Inc. • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
Heart pump may boost survival in complex stenting
Disease control OngoingThis study tests whether using the Impella heart pump during a high-risk stenting procedure helps people with weak hearts and blocked arteries. About 1,250 participants will be randomly assigned to get either Impella-supported stenting or standard care. The goal is to see if the …
Sponsor: Abiomed Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New heart pump aims to make risky artery procedures safer
Disease control By invitation onlyThis study tests the Impella ECP, a temporary heart pump, in 856 adults undergoing high-risk angioplasty (a procedure to open blocked heart arteries). The pump is inserted before the procedure to help keep blood flowing. Researchers will track major heart and brain complications,…
Sponsor: Abiomed Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Heart pump before angioplasty may limit attack damage
Disease control OngoingThis study tests if using a temporary heart pump (Impella CP) for 30 minutes before opening a blocked artery can reduce heart muscle damage in people having a severe heart attack. About 527 adults with a first-time anterior heart attack are enrolled. The goal is to see if this ap…
Sponsor: Abiomed Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New heart pump trial offers hope for severe heart failure patients
Disease control OngoingThis early study tests a temporary heart pump called Impella BTR in 10 adults with severe heart failure. The pump is placed inside the body to help the heart pump blood for up to 28 days. The goal is to see if the device is safe and can support patients until they recover or rece…
Sponsor: Abiomed Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New heart pump may reduce death and stroke in risky surgeries
Disease control OngoingThis study tests the Impella 5.5 heart pump in 123 high-risk patients with weak hearts (ejection fraction 25% or less) who need complex cardiac surgery. The pump supports the heart during and after surgery to prevent failure, stroke, and other complications. The goal is to confir…
Sponsor: Abiomed Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC